ライブ
BioPharma DiveSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyEndpoints NewsSummit withdraws $500M offering, citing 'market conditions'Clinical OMICsLipid-Protein Biomarker Makes Clinical Debut with Early Ovarian Cancer DetectionEndpoints NewsSensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyEndpoints NewsCamurus’ second CRL for acromegaly drug; Teva details workforce cutsFierceBiotechFierce Biotech heading to UK to host event amid London Life Sciences WeekEndpoints NewsBiopharma pay report: Top-paid CSOs, CMOs of 2025Endpoints NewsKardigan plans $320M IPO for heart drugs as Nasdaq listings gain steamPharmaVoiceCompetition is brewing between ADCs and bispecificsBioWorldInnovo Therapeutics synthesizes new NMT1 inhibitorsBioWorldShanghai Qingrun Pharmaceutical Technology patents new Mat2A inhibitorsBioWorldSalubris Pharma reports new RXFP1 receptor agonists
FierceBiotech 2026年1月20日

Former Spero execs fined by SEC over antibiotic efficacy claims

Former Spero execs fined by SEC over antibiotic efficacy claims

原文
本文は利用できません。元の情報源をご確認ください。